LEAMINGTON, Ontario – Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced that its medical cannabis division, Tilray Medical, has expanded its medical cannabis offering and launched the first EU GMP medical cannabis oil products in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis.
Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said, “Demand for medical cannabis in Malta is growing rapidly and we are incredibly proud to service patients with the high-quality medical cannabis products they rely on and in the formats they prefer.”
In Malta, patients may obtain prescriptions for medical cannabis and a medical cannabis card through family doctors. Medical cannabis cards are issued by Malta’s Superintendent of Public Health.
Tilray has a pioneering track record as a company committed to making EU GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need around the world and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
(This information is primarily sourced from Tilray Brands, Inc. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).